• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对 SARS-CoV-2 NSP13 解旋酶可成药性口袋的计算洞察。

In Silico Insights towards the Identification of SARS-CoV-2 NSP13 Helicase Druggable Pockets.

机构信息

Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, 98166 Messina, Italy.

出版信息

Biomolecules. 2022 Mar 22;12(4):482. doi: 10.3390/biom12040482.

DOI:10.3390/biom12040482
PMID:35454070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9029846/
Abstract

The merging of distinct computational approaches has become a powerful strategy for discovering new biologically active compounds. By using molecular modeling, significant efforts have recently resulted in the development of new molecules, demonstrating high efficiency in reducing the replication of severe acute respiratory coronavirus 2 (SARS-CoV-2), the agent responsible for the COVID-19 pandemic. We have focused our interest on non-structural protein Nsp13 (NTPase/helicase), as a crucial protein, embedded in the replication-transcription complex (RTC), that controls the virus life cycle. To assist in the identification of the most druggable surfaces of Nsps13, we applied a combination of four computational tools: FTMap, SiteMap, Fpocket and LigandScout. These software packages explored the binding sites for different three-dimensional structures of RTC complexes (PDB codes: 6XEZ, 7CXM, 7CXN), thus, detecting several hot spots, that were clustered to obtain ensemble consensus sites, through a combination of four different approaches. The comparison of data provided new insights about putative druggable sites that might be employed for further docking simulations on druggable surfaces of Nsps13, in a scenario of repurposing drugs.

摘要

不同计算方法的融合已成为发现新的具有生物活性化合物的有力策略。最近,通过使用分子建模,大量的努力已经开发出了新的分子,这些分子在降低严重急性呼吸冠状病毒 2(SARS-CoV-2)的复制方面表现出了很高的效率,SARS-CoV-2 是导致 COVID-19 大流行的病原体。我们的兴趣集中在非结构蛋白 Nsp13(NTPase/解旋酶)上,它是一种嵌入复制转录复合物(RTC)中的关键蛋白,控制着病毒的生命周期。为了帮助识别 Nsps13 最适合成药的表面,我们应用了四种计算工具的组合:FTMap、SiteMap、Fpocket 和 LigandScout。这些软件包探索了不同 RTC 复合物三维结构(PDB 代码:6XEZ、7CXM、7CXN)的结合位点,从而检测到了几个热点,通过四种不同方法的组合,将它们聚类以获得一致的共识结合位点。数据的比较提供了关于可能用于进一步对接模拟 Nsps13 成药表面的潜在成药部位的新见解,这是一种药物再利用的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/64b73e82ba78/biomolecules-12-00482-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/602da1613485/biomolecules-12-00482-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/5a94b38ad071/biomolecules-12-00482-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/a2114e7fff5d/biomolecules-12-00482-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/b30960d7d4f1/biomolecules-12-00482-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/64b73e82ba78/biomolecules-12-00482-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/602da1613485/biomolecules-12-00482-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/5a94b38ad071/biomolecules-12-00482-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/a2114e7fff5d/biomolecules-12-00482-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/b30960d7d4f1/biomolecules-12-00482-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd76/9029846/64b73e82ba78/biomolecules-12-00482-g005.jpg

相似文献

1
In Silico Insights towards the Identification of SARS-CoV-2 NSP13 Helicase Druggable Pockets.针对 SARS-CoV-2 NSP13 解旋酶可成药性口袋的计算洞察。
Biomolecules. 2022 Mar 22;12(4):482. doi: 10.3390/biom12040482.
2
Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.利用计算片段筛选技术绘制主要 SARS-CoV-2 药物靶点图谱并评估其成药性:鉴定 Nsp13 解旋酶上的别构小分子结合位点。
PLoS One. 2021 Feb 17;16(2):e0246181. doi: 10.1371/journal.pone.0246181. eCollection 2021.
3
Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach.靶向 SARS-CoV-2 nsp13 解旋酶及评估其成药性口袋:通过多靶点计算机药物重定位方法鉴定两种有效的抑制剂。
Molecules. 2022 Nov 3;27(21):7522. doi: 10.3390/molecules27217522.
4
A Repurposed Drug Interferes with Nucleic Acid to Inhibit the Dual Activities of Coronavirus Nsp13.一种重新利用的药物干扰核酸以抑制冠状病毒 Nsp13 的双重活性。
ACS Chem Biol. 2024 Jul 19;19(7):1593-1603. doi: 10.1021/acschembio.4c00244. Epub 2024 Jul 9.
5
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase.通过筛选小分子抑制剂鉴定 SARS-CoV-2 抗病毒化合物。
Biochem J. 2021 Jul 16;478(13):2405-2423. doi: 10.1042/BCJ20210201.
6
SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts.严重急性呼吸综合征冠状病毒-2 的 Nsp13 具有 NTP 酶和 RNA 解旋酶活性,可被铋盐抑制。
Virol Sin. 2020 Jun;35(3):321-329. doi: 10.1007/s12250-020-00242-1. Epub 2020 Jun 4.
7
Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?我们是否应该尝试使用 SARS-CoV-2 解旋酶抑制剂治疗 COVID-19?
Arch Med Res. 2020 Oct;51(7):733-735. doi: 10.1016/j.arcmed.2020.05.024. Epub 2020 May 31.
8
In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity.基于计算机的 2-氨基环丁酮与 SARS-CoV-2 Nsp13 解旋酶的结合及其抗病毒活性的验证。
Int J Mol Sci. 2023 Mar 7;24(6):5120. doi: 10.3390/ijms24065120.
9
structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)非结构蛋白13(Nsp13)解旋酶和Nsp14的结构建模以及美国食品药品监督管理局(FDA)批准的抗病毒药物作为双重抑制剂的重新利用
Gene Rep. 2020 Dec;21:100860. doi: 10.1016/j.genrep.2020.100860. Epub 2020 Aug 28.
10
Identification of Potential Inhibitors of the SARS-CoV-2 NSP13 Helicase via Structure-Based Ligand Design, Molecular Docking and Nonequilibrium Alchemical Simulations.通过基于结构的配体设计、分子对接和非平衡热力学模拟鉴定 SARS-CoV-2 NSP13 解旋酶的潜在抑制剂。
ChemMedChem. 2024 May 17;19(10):e202400095. doi: 10.1002/cmdc.202400095. Epub 2024 Mar 25.

引用本文的文献

1
Classification of likely functional class for ligand binding sites identified from fragment screening.从片段筛选中鉴定出的配体结合位点的可能功能分类。
Commun Biol. 2024 Mar 13;7(1):320. doi: 10.1038/s42003-024-05970-8.

本文引用的文献

1
Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase.结构、机制与 SARS-CoV-2 NSP13 解旋酶的晶体碎片筛选
Nat Commun. 2021 Aug 11;12(1):4848. doi: 10.1038/s41467-021-25166-6.
2
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase.通过筛选小分子抑制剂鉴定 SARS-CoV-2 抗病毒化合物。
Biochem J. 2021 Jul 16;478(13):2405-2423. doi: 10.1042/BCJ20210201.
3
Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.
基于结构的虚拟筛选鉴定出 SARS-CoV-2 解旋酶的 RecA 结构域的多个稳定结合位点。
Molecules. 2021 Mar 7;26(5):1446. doi: 10.3390/molecules26051446.
4
Coronaviruses.冠状病毒
Expert Opin Ther Pat. 2021 Apr;31(4):291-294. doi: 10.1080/13543776.2021.1901402. Epub 2021 Mar 30.
5
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents.冠状病毒解旋酶:抗病毒药物开发和治疗专利的有吸引力和独特的靶标。
Expert Opin Ther Pat. 2021 Apr;31(4):339-350. doi: 10.1080/13543776.2021.1884224. Epub 2021 Apr 21.
6
Potential drug targets of SARS-CoV-2: From genomics to therapeutics.新型冠状病毒的潜在药物靶点:从基因组学到治疗学。
Int J Biol Macromol. 2021 Apr 30;177:1-9. doi: 10.1016/j.ijbiomac.2021.02.071. Epub 2021 Feb 9.
7
Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis.Cryo-EM 结构揭示了 SARS-CoV-2 复制和转录复合物的延伸结构,该结构显示了帽合成中的中间状态。
Cell. 2021 Jan 7;184(1):184-193.e10. doi: 10.1016/j.cell.2020.11.016. Epub 2020 Nov 14.
8
Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19.与 SARS-CoV-2 感染相关的基本功能分子:COVID-19 的潜在治疗靶点。
Gene. 2021 Feb 5;768:145313. doi: 10.1016/j.gene.2020.145313. Epub 2020 Nov 18.
9
Architecture of a SARS-CoV-2 mini replication and transcription complex.SARS-CoV-2 迷你复制和转录复合物的结构。
Nat Commun. 2020 Nov 18;11(1):5874. doi: 10.1038/s41467-020-19770-1.
10
Coronavirus biology and replication: implications for SARS-CoV-2.冠状病毒的生物学与复制:对 SARS-CoV-2 的启示。
Nat Rev Microbiol. 2021 Mar;19(3):155-170. doi: 10.1038/s41579-020-00468-6. Epub 2020 Oct 28.